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Abstract 
The publication of the Mycobacterium tuberculosis genome sequence in 1998 heralded a new phase in mycobacterial 
research. The subsequent decade has seen an enormous increase in our understanding of the basic biology, virulence 
mechanisms, drug targets and evolution of the M. tuberculosis complex, an acceleration in knowledge that would not 
have been possible without the genome. This review summarises some key findings from mycobacterial genomics and 
highlights how this knowledge can be applied to disease control in the developing world.  [Ethiop.J.Health Dev. 
2008;22(Special Issue):119-122]  
 
Introduction 
From anywhere in the world with an internet connection, 
researchers can now access the genome sequences of all 
the major mycobacterial pathogens, such as 
Mycobacterium tuberculosis1, Mycobacterium leprae2, 
Mycobacterium bovis3 and Mycobacterium ulcerans4, as 
well as the vaccine strains M. bovis BCG5 and 
Mycobacterium microti OV2546. Indeed, through the 
Wellcome Trust Sanger Institute7, The Institute for 
Genome Research8, and the Broad Institute9  we currently 
have genome sequences for six different strains of M. 
tuberculosis (H37Rv, CDC1551, 210, C, F11, Haarlem), 
with many more to follow through projects underway at 
the Broad. The “TubercuList” M. tuberculosis H37Rv 
genome database regularly receives more than 70,000 
“hits” per month from all over the world (S. Cole, personal 
communication), showing how the genome has become a 
cornerstone of mycobacterial research; we now all work in 
a post-genomic landscape.  
 
How has the availability of this mass of genome data 
changed our understanding of the tubercle bacilli? How 
are we to apply this information to improve disease 
control? This review will briefly summarise key findings 
from the genome sequences of M. tuberculosis, M. bovis 
and M. bovis BCG, and highlight how genome findings are 
being applied in the fight against disease.  
 
Evolution 
The emergence of M. tuberculosis has often been viewed 
as a classic zoonotic infection, with the generalist animal 
pathogen M. bovis crossing the species barrier into man at 
the time of cattle domestication. Initial work on defining 
genetic diversity across the M. tuberculosis complex using 
single nucleotide polymorphisms (SNPs) suggested that 
M. tuberculosis arose ~15,000 years ago (1), a similar date 
to that proposed for cattle domestication (2), seemingly 
providing further support for the zoonosis model. 
However, subsequent attempts to date the clonal 
expansion of M. tuberculosis using SNP data gave a date 
of ~35,000 years ago (3). Indeed, using SNP data to define 






a molecular clock may not be appropriate for M. 
tuberculosis, given its small effective population size and 
distinctive DNA repair systems. 
 
An alternative method to explore the evolution of the M. 
tuberculosis complex employed comparative genomics. 
With the M. tuberculosis genome as a starting point, the 
genomes of all members of the M. tuberculosis complex 
were scanned for deletion events (4). This defined a set of 
12 deletions that could then be mapped across a reference 
collection that encompassed the diversity of the M. 
tuberculosis complex (5). This comparative analysis 
allowed a novel evolutionary scenario to be proposed, with 
M. tuberculosis closer to the common ancestor of the 
complex than M. bovis (Figure 1). This scenario appears 
to overturn conventional evolutionary thinking, 
suggesting that tuberculosis is in fact a reverse zoonosis 
given by man to domesticated animals. However, the host 
association of the common ancestor of the complex is 
unknown, and valid cases can be made for a human or 
animal associated ancestor. 
 
Recent work from strains causing tuberculosis in East 
Africa has added a further twist to the evolution of the M. 
tuberculosis complex (6). These strains, classed as 
“smooth” tubercle bacilli due to their characteristic colony 
appearance, were characterised using multilocus 
sequencing and revealed to have an unexpected degree of 
sequence variation. However, most surprising was 
evidence for horizontal gene transfer among this 
population of strains, which goes against current data 
suggesting a purely clonal population structure for the M. 
tuberculosis complex. Based on these data the authors 
proposed that these in fact were isolates of the progenitor 
of the M. tuberculosis complex, Mycobacterium 
prototuberculosis (6). However, this latter suggestion has 
been challenged since recombination within the studied 
population would inflate the estimation of diversity of this 
group (7). Clearly, a greater sampling of strains causing 
tuberculosis on a worldwide level, and in particular from 
Africa, is needed to allow a better understanding of how 
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smooth tubercle bacilli fit into the evolution of the M. 
tuberculosis complex. 
Using a combination of genome deletion events and SNPs 
it is possible to define a phylogeny for the members of the 
M. tuberculosis complex, with M. tuberculosis sitting 
closer to the common ancestor than M. bovis. The deletion 
events RD9 and RD4 serve as unequivocal markers of 
species; hence, strains deleted for RD9 and RD4 are 
defined as M. bovis. The mmpL6 SNP is at codon 561, 
where AAC is replaced by AAG; hence, M. bovis presents 















Analysis of the genome sequence of M. tuberculosis 
revealed a remarkable capacity for both catabolism and 
anabolism of lipids, reflecting complex synthetic 
requirements for the cell wall and the capacity to 
metabolise a wide variety of lipid substrates (8). The 
radiance of lipid metabolic genes is found across all 
members of the M. tuberculosis complex; however, 
comparative analysis of genes encoding key enzymes of 
central metabolism has uncovered the metabolic basis for 
notable phenotypic differences between the tubercle 
bacilli. For example, M. bovis requires pyruvate to be 
added to media where glycerol is the sole carbon source, 
while M. tuberculosis has no such requirement; the 
metabolic basis for this was unknown, but the answer 
presumably lay in the glycerol utilisation pathway. Once 
the M. bovis genome had been sequenced, it was relatively 
facile to compare all genes between M. bovis and M. 
tuberculosis that encoded proteins involved in glycerol 
utilisation. This revealed a nonsynonymous point 
mutation in the gene encoding pyruvate kinase which 
chaged a conserved glutamic acid residue to aspartic acid 
(9). Enzyme assays showed that M. bovis lacked pyruvate 
kinase activity, while complementation with the M. 
tuberculosis allele restored pyruvate kinase activity and 
the ability to grow on glycerol. Furthermore, the 
complemented strains of M. bovis switched from the 
typical “dysgonic” appearance of M. bovis colonies on 
glycerol-based media to abundant, “eugonic” colonies as 
seen with M. tuberculosis.  As pyruvate kinase is one of 
the few irreversible steps in glycolysis, the lack of a 
functional pyruvate kinase in M. bovis blocks glycolytic 
intermediates from feeding into oxidative metabolism. 
Hence, in vivo, M. bovis must rely on amino acids or fatty-
acids as a carbon source for energy metabolism; in vitro, 




The current length of tuberculosis chemotherapy and 
paucity of frontline drugs are driving the emergence of 
MDR (multi-drug resistant) and XDR (extensively drug 
resistant) strains. There is clearly an immediate need for 
novel drug targets to be identified in M. tuberculosis. 
Genomics and allied functional genomic techniques have 
helped galvanize drug discovery initiatives. A key starting 
point was to identify which of the ~4000 genes are 
essential for the bacillus, as proteins essential for bacterial 
viability are considered the most promising targets for 
rational drug design. Using a combination of saturation 
transposon mutagenesis and microarray-based 
identification of insertion sites, Sassetti, Boyd and Rubin 
defined a minimal in vitro gene set for M. tuberculosis 
(10); 570 of these genes were also found to be essential by 
a similar experimental approach adopted by Bishai and 
colleagues (11). To prioritize these genes as targets for 
drug development further genomic criteria can be used, 
including the presence of druggable protein domains that 
bind potent compounds, situation at a unique position in a 
metabolic chain or “chokepoint”, or phylogenetic 
restriction to avoid homologues in host or host flora.   
 
In addition to identifying potential targets for drugs, 
genomics has greatly assisted in identifying the targets of 
drugs with known antibacterial activity. Previously this 
had to be done by laborious and time consuming genetic 
screens but the ease of full genome sequencing means 
whole genome comparisons can be used to locate 
Common ancestor (unknown host) 
M. bovis M. tuberculosis M. africanum M. microti 
 mmpL6 SNP RD4 
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resistance-conferring mutations. For example the 
molecular target for the diaryquinoline R207910 was 
identified by comparing the genomes of resistant M. 
tuberculosis and M. smegmatis strains selected in vitro 
with the wild-type genome. Drug resistance conferring 
mutations localised in both species to the atpE genes, that 
encodes part of the ATP synthase, which was subsequently 
confirmed as the site of drug action (12). PA-824 is a 
nitroimidazole prodrug whose activation requires 
reduction via an F420-dependent glucose-6-phosphate 
dehydrogenase; however, this activity is not sufficient to 
confer sensitivity. To identify further factors involved in 
sensitivity to PA-824, Barry and colleagues isolated PA-
824 resistant strains with wild-type F420-dependent 
glucose-6-phosphate dehydrogenase activity, and 
resequenced their genomes using high density 
oligonucleotide arrays (13). Resistant isolates were shown 
to harbour mutations in Rv3547, encoding a novel 
nitroimidazo-oxazine-specific nitroreductase, further 
elucidating the action of PA824. This approach of rapid 
full genome comparisons also represents a powerful new 
tool for characterizing the phenotypic consequences of 
single point mutations in other settings, such as the 
microevolution of M. tuberculosis within hosts or during 
transmission cycles.  
 
BCG: a family of duplicating daughters 
BCG is not a single vaccine, but rather a family of 
daughter strains derived from an original stock sent out by 
the Institute Pasteur to laboratories around the world (14). 
Accumulating evidence suggests that these daughter 
strains posses significant differences in terms of genome 
content, immunostimulatory activity, and protective 
efficacy. Indeed, despite being the most widely used 
vaccine in the world, the molecular basis for the 
attenuation of BCG has never been fully described, 
although the loss of the RD1 locus was a key attenuating 
event (15). The recent completion of the genome sequence 
of M. bovis BCG Pasteur, and comparative analyses across 
BCG daughter strains, exposed all the all genetic 
differences between BCG Pasteur and the virulent M. 
bovis and M. tuberculosis, and provided further evidence 
for strain specific genome content that may impact on 
vaccine efficacy (16). 
 
A key finding from the BCG sequencing project was the 
presence of duplication events in the BCG genome. These 
duplications are the first to be described in a mycobacterial 
genome, and show variable configurations across the 
daughter strains. For example, DU1 is a duplication 
around the origin of chromosomal replication, oriC, that is 
only found in BCG Pasteur. On the other hand, DU2 
defines a duplication that is present in all BCG strains, but 
in 4 different arrangements. Hence, after the original DU2 
duplication event, internal regions were spliced out and 
duplicated a number of times, suggesting a selective 
pressure was driving the gene duplication events. Clues to 
what the in vitro selective pressure was are revealed in the 
core region of DU2 which is duplicated across the strains 
but that did not subsequently undergo deletion. This core 
region comprises three complete coding sequences (CDS), 
namely glpD2 (encoding a putative glycerol 3-P 
dehydrogenase), phoY1 (encoding a potential repressor of 
the high affinity phosphate uptake system), and Rv3300c 
(encoding a protein of unknown function). This 
duplication would serve to increase the production of 
glycerol 3-P dehyrogenase; glycerol was the carbon source 
used by Calmette and Guérin during the derivation of BCG 
from M. bovis, so it is possible that increased copy number 
of glpD2 conferred a selective advantage for growth on 
glycerol. However, glycerol 3-P dehyrogenase is not a 
known metabolic bottleneck for glycerol growth; one 
might instead expect to have seen glpK, encoding glycerol 
kinase and a known rate limiting enzyme in glycerol 
utilisation, undergoing amplification. A second possibility 
is that increased production of the potential repressor of 
high affinity phosphate uptake, phoY1, was selected. BCG 
is known to have lesions in the high affinity phosphate 
uptake system compared to M. bovis and M. tuberculosis, 
suggesting that switching this system off may have been 
advantageous to the bacillus.  
 
Application to disease control 
In a collaborative project between the Armauer Hansen 
Research Institute (Ethiopia), Imperial College (UK), 
Trinity College (Ireland), the Swiss Tropical Institute 
(Switzerland), the Institute for Livestock Research 
(Kenya), and VLA (UK), we aim to measure the cost of 
bovine TB to Ethiopian society by assessing its impact on 
livestock productivity and human health. A necessary step 
in this project is to ensure that we can correctly culture and 
discriminate the members of the M. tuberculosis complex 
from both human and animal clinical samples. Findings 
from the mycobacterial genome projects feed directly into 
this endeavour. For example, from the M. bovis genome 
project we know that M. bovis can not use carbohydrates 
as a carbon source for energy production; pyruvate must 
be added to the media to allow M. bovis to grow (9). 
Hence, knowledge from the genome informs our choice of 
media for the improved isolation of M. bovis from clinical 
samples. Similarly, from comparative genomics we now 
know that deletion events provide unequivocal markers of 
species (5, 17). From the schematic in Figure 1, we can see 
that isolates that are deleted for RD9 and RD4 are M. 
bovis, while strains that have the RD9 and RD4 loci intact 
are M. tuberculosis. The presence or absence of these 
deletions can be determined using a simple PCR reaction; 
this is a significant improvement over biochemical tests 
(such as nitrate reduction or niacin production) which can 
prove misleading. Hence, genetic tests based on deletions 
provide confidence that the isolates are correctly identified 
as M. bovis or M. tuberculosis. Access to a specific, 
portable PCR for strain discrimination is an obvious 
benefit when one is trying to determine the burden of M. 
bovis infection in the human population.  
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Conclusions 
Genomics has fundamentally altered our understanding of 
the members of the M. tuberculosis complex. The 
advances outlined above are also providing tools that can 
now be applied to disease control, with simple PCR-based 
strain identification offering a case in point. A key 
requirement is to ensure that mycobacterial genomics 
continues to drive efforts in disease control, and that novel 
findings are translated to the clinical and field setting 
where their application can have the greatest impact.  
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